Skip to content

Merck’s Covid Pill Shows Activity Against Omicron in Lab

  • EU regulators reviewing company’s molnupiravir for clearance
  • U.K. prepares to roll out Pfizer drug for immunocompromised
Merck & Co. and Ridgeback Biotherapeutics LP’s Molnupiravir antiviral medication.

Merck & Co. and Ridgeback Biotherapeutics LP’s Molnupiravir antiviral medication.

Photographer: Kobi Wolf/Bloomberg
Updated on

Merck & Co.’s Covid-19 pill showed activity against omicron in six laboratory studies that raise confidence in the ability of the new therapy to battle the contagious, dominant variant. 

The independent studies from the U.S. and five European countries examined the impact of Merck’s molnupiravir and other antivirals against variants of concern including omicron, Merck and partner Ridgeback Biotherapeutics LP said Friday in a statement